Antiviral_Drugs.ppt

Dr  Sumitha Jagadibabu
Dr Sumitha JagadibabuAssociate Professor à JBAS College for Women
ANTiviral drugs
CHEnnai
Dr Sumitha J
Antiviral agents
• Antiviral agents are medications used to treat viral infections
by inhibiting the replication of viruses or reducing their
ability to cause disease.
Types of Antiviral Agents
• Antiviral agents can be classified into several categories based on their mechanism of action:
• Entry Inhibitors: These drugs prevent the virus from entering host cells. Examples include fusion
inhibitors and attachment inhibitors.
• Nucleoside/Nucleotide Analogues: These drugs mimic the building blocks of DNA or RNA and
interfere with viral replication. Examples include acyclovir and tenofovir.
• Protease Inhibitors: These drugs target viral proteases required for viral replication. They are
commonly used in treating HIV and hepatitis C.
• Polymerase Inhibitors: These drugs inhibit viral enzymes (e.g., reverse transcriptase,
polymerase) involved in replicating the viral genome. Examples include zidovudine and
sofosbuvir.
• Neuraminidase Inhibitors: These drugs inhibit neuraminidase, an enzyme necessary for the
release of new virus particles. Oseltamivir is a well-known example.
Mechanism of Action
• antiviral agents interfere with specific stages of the viral life
cycle, including attachment, entry, replication, and release
Mechanism of Action
Attachment Inhibition: Viruses must first attach to specific receptors on
the surface of host cells to initiate infection. Antiviral agents can
interfere with this attachment process by:
• Competitive Binding: These agents mimic host cell receptors and compete with the virus for
binding sites. When the virus binds to the antiviral agent instead of the host cell receptor, it can't
initiate infection.
• Blocking Receptor Sites: Some drugs block or mask the viral binding sites on host cells, preventing
the virus from attaching.
Mechanism of Action
Entry Inhibition:After attachment, the virus needs to enter the host cell.
Antiviral agents can interfere with this step by:
• Fusion Inhibition: Fusion inhibitors, like enfuvirtide for HIV, block the fusion of viral and cellular
membranes, preventing the virus from entering the host cell.
• Endocytosis Inhibition: Some antiviral drugs can inhibit the endocytosis process that viruses use
to enter cells.
Mechanism of Action
Replication Inhibition: Once inside the host cell, viruses use the host's
machinery to replicate their genetic material and produce new viral
particles. Antiviral agents can disrupt this replication process by
targeting:
• Nucleoside/Nucleotide Analogues: These drugs resemble the building blocks of DNA or RNA and get
incorporated into the viral genome during replication, causing mutations and preventing further
replication. Examples include acyclovir and tenofovir.
• Protease Inhibitors: These drugs target viral proteases required for processing viral proteins,
preventing the formation of functional viral particles. They are commonly used in treating HIV and
hepatitis C.
• Polymerase Inhibitors: These drugs inhibit viral enzymes (e.g., reverse transcriptase, polymerase)
involved in replicating the viral genome.
Mechanism of Action
Release Inhibition:After replication, viruses must exit the host
cell to spread and infect other cells. Antiviral agents can
interfere with this release step by:
• Neuraminidase Inhibition: Neuraminidase is an enzyme required for the release of new
virus particles from host cells. Inhibiting this enzyme prevents the release of viruses.
Oseltamivir (Tamiflu) is an example used for influenza.
Selectivity and Resistance
• Selectivity of Antiviral Agents:
• Antiviral agents are designed to specifically target viral
processes, such as attachment, replication, or release, without
interfering with normal host cell functions. This selectivity is
essential for minimizing side effects and preserving the health of
the host.
• Selectivity is achieved by identifying unique viral targets or
processes that are distinct from those found in host cells. For
example, targeting viral enzymes or proteins that have no direct
equivalent in human cells.
• By specifically interfering with viral processes, antiviral agents
aim to disrupt the viral life cycle while leaving host cell functions
• Development of Drug Resistance:
• Viruses can develop resistance to antiviral agents over time due to
genetic mutations. This phenomenon is similar to the development of
antibiotic resistance in bacteria.
• When antiviral agents are used to treat viral infections, some viruses
may acquire mutations in their genetic material that confer resistance
to the drug. These mutations can occur naturally during viral
replication.
• Drug-resistant viral variants have changes in their viral targets (e.g.,
enzymes or proteins) that reduce the drug's ability to bind or inhibit
the viral process effectively. As a result, the drug becomes less
effective or completely ineffective against the resistant virus.
• The emergence of drug-resistant viruses is a significant concern in
Side effetcts
• Gastrointestinal Disturbances: Many antiviral drugs can cause
gastrointestinal side effects, including nausea, vomiting, diarrhea, or
abdominal discomfort. Patients should be advised to take these
medications with food or as directed to minimize these effects.
• Fatigue: Fatigue is a common side effect of antiviral therapy.
Patients may experience decreased energy levels and overall
tiredness.
• Headache: Headaches are often reported by individuals taking
antiviral drugs, particularly during the initial stages of treatment.
• Skin Reactions: Some antiviral drugs can lead to skin reactions,
such as rashes, itching, or hypersensitivity reactions. Patients
Side effetcts
• Liver and Kidney Function: Certain antiviral drugs can affect liver or
kidney function. Monitoring liver enzyme levels and kidney function
through blood tests is essential to detect any abnormalities early.
• Hematological Effects: Some antiviral drugs can cause
hematological side effects, including anemia, neutropenia (low white
blood cell count), or thrombocytopenia (low platelet count). Regular
blood tests are necessary to monitor these parameters.
• Psychiatric Symptoms: In some cases, antiviral therapy can lead to
mood changes or psychiatric symptoms. Patients and caregivers
should be educated about these potential side effects and
encouraged to seek help if necessary
Antiviral_Drugs.ppt
Case Studies
• Case Study 1:Patient Scenario:
• A 28-year-old sexually active male presents with symptoms
of painful genital sores and flu-like symptoms. He has a
history of multiple sexual partners and has not been
consistently using protection. A clinical evaluation and
testing confirm a diagnosis of genital herpes (HSV-2
infection).
Group Activity
• Review the patient's medical history, symptoms, and
diagnostic results.
• Discuss the mechanisms of action of antiviral drugs used to
treat HSV infections.
• Recommend an appropriate antiviral treatment, including
the drug name, dosage, and duration of therapy.
• Consider the importance of patient education regarding
transmission prevention and managing recurrent outbreaks.
Case Studies
• Case Study 2:Patient Scenario:
• A 55-year-old patient with a history of intravenous drug use
presents with persistent fatigue, abdominal pain, and dark urine.
Laboratory tests show elevated liver enzymes, and further testing
confirms a chronic hepatitis C infection.
Group Activity
• Explore the mechanisms of action of antiviral drugs used to treat
chronic hepatitis C.
• Consider the patient's medical history, current symptoms, and
liver function tests.
• Recommend an appropriate antiviral treatment regimen,
including specific antiviral drugs, their doses, and duration.
• Discuss the potential side effects and drug interactions and how
to monitor and manage them.
• Highlight the importance of adherence and regular monitoring to
assess treatment response.
CASE STUDIES
• Case Study 3:Patient Scenario:
• A 45-year-old healthcare worker tests positive for COVID-19.
The patient is mildly symptomatic with fever, cough, and
fatigue. They have no known allergies or significant
comorbidities.
Group Activity
• Research and discuss the available antiviral treatments for
COVID-19.
• Consider the patient's mild symptoms, occupation, and
comorbidities.
• Recommend an appropriate antiviral treatment strategy,
including specific drugs (if applicable), dosages, and
duration.
• Discuss potential side effects and monitoring parameters for
COVID-19 treatment.
• Emphasize the importance of isolation, infection control
1 sur 19

Recommandé

Rhabdo Virus.pptx par
Rhabdo Virus.pptxRhabdo Virus.pptx
Rhabdo Virus.pptxDr Sumitha Jagadibabu
114 vues17 diapositives
HICC.pdf par
HICC.pdfHICC.pdf
HICC.pdfDr Sumitha Jagadibabu
216 vues3 diapositives
Corona Virus.pptx par
Corona Virus.pptxCorona Virus.pptx
Corona Virus.pptxDr Sumitha Jagadibabu
154 vues19 diapositives
Rubella Virus.pptx par
Rubella Virus.pptxRubella Virus.pptx
Rubella Virus.pptxDr Sumitha Jagadibabu
146 vues13 diapositives
HAI.pdf par
HAI.pdfHAI.pdf
HAI.pdfDr Sumitha Jagadibabu
163 vues2 diapositives
DNA VIRUS REPLICATION par
DNA VIRUS REPLICATIONDNA VIRUS REPLICATION
DNA VIRUS REPLICATIONBhagraj Godara
2.3K vues18 diapositives

Contenu connexe

Tendances

Viral assay par
Viral assay Viral assay
Viral assay J K COLLEGE,PURULIA
9.1K vues7 diapositives
Pox virus par
Pox virusPox virus
Pox virusArchana Shaw
5.1K vues26 diapositives
POXVIRUSES.pptx par
POXVIRUSES.pptxPOXVIRUSES.pptx
POXVIRUSES.pptxSamarthSharma532120
221 vues24 diapositives
An introduction to virology par
An introduction to virologyAn introduction to virology
An introduction to virologyKaveh Haratian
7K vues129 diapositives
Baltimore classification virus par
Baltimore classification  virusBaltimore classification  virus
Baltimore classification virusSuganyaPaulraj
3.1K vues31 diapositives

Tendances(20)

Baltimore classification virus par SuganyaPaulraj
Baltimore classification  virusBaltimore classification  virus
Baltimore classification virus
SuganyaPaulraj3.1K vues
Oncogenic viruses par jeeva raj
Oncogenic virusesOncogenic viruses
Oncogenic viruses
jeeva raj10.6K vues
Tumour Viruses par raj kumar
Tumour VirusesTumour Viruses
Tumour Viruses
raj kumar22.5K vues
Classification of virus par saran96
Classification of virusClassification of virus
Classification of virus
saran969.8K vues

Similaire à Antiviral_Drugs.ppt

Chp no 2 anti-microbial.pptx par
Chp no 2 anti-microbial.pptxChp no 2 anti-microbial.pptx
Chp no 2 anti-microbial.pptxMahnoorFatima92
5 vues21 diapositives
Antibiotic policy par
Antibiotic policyAntibiotic policy
Antibiotic policyMona Mustafa
13.8K vues40 diapositives
Antibiotic policy par
Antibiotic policyAntibiotic policy
Antibiotic policywisam alsaedi
565 vues40 diapositives
ANTIVIRAL DRUGS.ppt par
ANTIVIRAL DRUGS.pptANTIVIRAL DRUGS.ppt
ANTIVIRAL DRUGS.pptAbwoneKenneth
28 vues103 diapositives
Antibiotic Resistance & stewardship program in children par
Antibiotic  Resistance & stewardship program in childrenAntibiotic  Resistance & stewardship program in children
Antibiotic Resistance & stewardship program in childrenAzad Haleem
2.3K vues32 diapositives
Immunotherapy of tumor par
Immunotherapy of tumorImmunotherapy of tumor
Immunotherapy of tumorsountharya Sen s
251 vues18 diapositives

Similaire à Antiviral_Drugs.ppt(20)

Antibiotic Resistance & stewardship program in children par Azad Haleem
Antibiotic  Resistance & stewardship program in childrenAntibiotic  Resistance & stewardship program in children
Antibiotic Resistance & stewardship program in children
Azad Haleem2.3K vues
Antibiotic; introduction & stewardship program in children par Azad Haleem
Antibiotic; introduction & stewardship program in childrenAntibiotic; introduction & stewardship program in children
Antibiotic; introduction & stewardship program in children
Azad Haleem4.8K vues
Rational use of antibiotics par ZeelNaik2
Rational use of antibioticsRational use of antibiotics
Rational use of antibiotics
ZeelNaik2109 vues
Antibiotics antiviral drugs used in HSV I & II , DRUGS USED IN HIV. par Vinitkumar MJ
Antibiotics antiviral drugs used in HSV I & II , DRUGS USED IN HIV.Antibiotics antiviral drugs used in HSV I & II , DRUGS USED IN HIV.
Antibiotics antiviral drugs used in HSV I & II , DRUGS USED IN HIV.
Vinitkumar MJ202 vues
0VERVIEW OF ANTIBIOTIC RESISTANCE 111.pptx par KrishnaSupalkar
0VERVIEW OF ANTIBIOTIC RESISTANCE 111.pptx0VERVIEW OF ANTIBIOTIC RESISTANCE 111.pptx
0VERVIEW OF ANTIBIOTIC RESISTANCE 111.pptx
KrishnaSupalkar226 vues
Prinicple of Anti microbial therapy dr.kanwar singh.ppt par UnnayanRaj
Prinicple of Anti microbial therapy dr.kanwar singh.pptPrinicple of Anti microbial therapy dr.kanwar singh.ppt
Prinicple of Anti microbial therapy dr.kanwar singh.ppt
UnnayanRaj10 vues
Hepatitis.ppt par Alick12
Hepatitis.pptHepatitis.ppt
Hepatitis.ppt
Alick125 vues

Plus de Dr Sumitha Jagadibabu

Structure,Function and Properties of Immune cells.pdf par
Structure,Function and Properties of Immune cells.pdfStructure,Function and Properties of Immune cells.pdf
Structure,Function and Properties of Immune cells.pdfDr Sumitha Jagadibabu
9 vues12 diapositives
ARBO Viruses.pdf par
ARBO Viruses.pdfARBO Viruses.pdf
ARBO Viruses.pdfDr Sumitha Jagadibabu
9 vues12 diapositives
TOXINS.pptx par
TOXINS.pptxTOXINS.pptx
TOXINS.pptxDr Sumitha Jagadibabu
12 vues17 diapositives
Paramyxovirus.pptx par
Paramyxovirus.pptxParamyxovirus.pptx
Paramyxovirus.pptxDr Sumitha Jagadibabu
11 vues12 diapositives
Orthomyxovirus.pptx par
Orthomyxovirus.pptxOrthomyxovirus.pptx
Orthomyxovirus.pptxDr Sumitha Jagadibabu
16 vues16 diapositives
Microbial Pathogenicity.pptx par
Microbial Pathogenicity.pptxMicrobial Pathogenicity.pptx
Microbial Pathogenicity.pptxDr Sumitha Jagadibabu
88 vues39 diapositives

Plus de Dr Sumitha Jagadibabu(20)

Dernier

Exploring the nature and synchronicity of early cluster formation in the Larg... par
Exploring the nature and synchronicity of early cluster formation in the Larg...Exploring the nature and synchronicity of early cluster formation in the Larg...
Exploring the nature and synchronicity of early cluster formation in the Larg...Sérgio Sacani
1.5K vues12 diapositives
2. Natural Sciences and Technology Author Siyavula.pdf par
2. Natural Sciences and Technology Author Siyavula.pdf2. Natural Sciences and Technology Author Siyavula.pdf
2. Natural Sciences and Technology Author Siyavula.pdfssuser821efa
13 vues232 diapositives
Factors affecting fluorescence and phosphorescence.pptx par
Factors affecting fluorescence and phosphorescence.pptxFactors affecting fluorescence and phosphorescence.pptx
Factors affecting fluorescence and phosphorescence.pptxSamarthGiri1
9 vues11 diapositives
Note on the Riemann Hypothesis par
Note on the Riemann HypothesisNote on the Riemann Hypothesis
Note on the Riemann Hypothesisvegafrank2
9 vues20 diapositives
Small ruminant keepers’ knowledge, attitudes and practices towards peste des ... par
Small ruminant keepers’ knowledge, attitudes and practices towards peste des ...Small ruminant keepers’ knowledge, attitudes and practices towards peste des ...
Small ruminant keepers’ knowledge, attitudes and practices towards peste des ...ILRI
7 vues6 diapositives
IMMUNODIAGNOSTICS KITS.pdf par
IMMUNODIAGNOSTICS KITS.pdfIMMUNODIAGNOSTICS KITS.pdf
IMMUNODIAGNOSTICS KITS.pdfvetrivel303632
31 vues10 diapositives

Dernier(20)

Exploring the nature and synchronicity of early cluster formation in the Larg... par Sérgio Sacani
Exploring the nature and synchronicity of early cluster formation in the Larg...Exploring the nature and synchronicity of early cluster formation in the Larg...
Exploring the nature and synchronicity of early cluster formation in the Larg...
Sérgio Sacani1.5K vues
2. Natural Sciences and Technology Author Siyavula.pdf par ssuser821efa
2. Natural Sciences and Technology Author Siyavula.pdf2. Natural Sciences and Technology Author Siyavula.pdf
2. Natural Sciences and Technology Author Siyavula.pdf
ssuser821efa13 vues
Factors affecting fluorescence and phosphorescence.pptx par SamarthGiri1
Factors affecting fluorescence and phosphorescence.pptxFactors affecting fluorescence and phosphorescence.pptx
Factors affecting fluorescence and phosphorescence.pptx
SamarthGiri19 vues
Note on the Riemann Hypothesis par vegafrank2
Note on the Riemann HypothesisNote on the Riemann Hypothesis
Note on the Riemann Hypothesis
vegafrank29 vues
Small ruminant keepers’ knowledge, attitudes and practices towards peste des ... par ILRI
Small ruminant keepers’ knowledge, attitudes and practices towards peste des ...Small ruminant keepers’ knowledge, attitudes and practices towards peste des ...
Small ruminant keepers’ knowledge, attitudes and practices towards peste des ...
ILRI7 vues
selection of preformed arch wires during the alignment stage of preadjusted o... par MaherFouda1
selection of preformed arch wires during the alignment stage of preadjusted o...selection of preformed arch wires during the alignment stage of preadjusted o...
selection of preformed arch wires during the alignment stage of preadjusted o...
MaherFouda18 vues
Presentation on experimental laboratory animal- Hamster par Kanika13641
Presentation on experimental laboratory animal- HamsterPresentation on experimental laboratory animal- Hamster
Presentation on experimental laboratory animal- Hamster
Kanika136416 vues
XUE: Molecular Inventory in the Inner Region of an Extremely Irradiated Proto... par Sérgio Sacani
XUE: Molecular Inventory in the Inner Region of an Extremely Irradiated Proto...XUE: Molecular Inventory in the Inner Region of an Extremely Irradiated Proto...
XUE: Molecular Inventory in the Inner Region of an Extremely Irradiated Proto...
Sérgio Sacani787 vues
Determination of color fastness to rubbing(wet and dry condition) by crockmeter. par ShadmanSakib63
Determination of color fastness to rubbing(wet and dry condition) by crockmeter.Determination of color fastness to rubbing(wet and dry condition) by crockmeter.
Determination of color fastness to rubbing(wet and dry condition) by crockmeter.
DNA manipulation Enzymes 2.pdf par NetHelix
DNA manipulation Enzymes 2.pdfDNA manipulation Enzymes 2.pdf
DNA manipulation Enzymes 2.pdf
NetHelix6 vues
Oral_Presentation_by_Fatma (2).pdf par fatmaalmrzqi
Oral_Presentation_by_Fatma (2).pdfOral_Presentation_by_Fatma (2).pdf
Oral_Presentation_by_Fatma (2).pdf
fatmaalmrzqi8 vues

Antiviral_Drugs.ppt

  • 2. Antiviral agents • Antiviral agents are medications used to treat viral infections by inhibiting the replication of viruses or reducing their ability to cause disease.
  • 3. Types of Antiviral Agents • Antiviral agents can be classified into several categories based on their mechanism of action: • Entry Inhibitors: These drugs prevent the virus from entering host cells. Examples include fusion inhibitors and attachment inhibitors. • Nucleoside/Nucleotide Analogues: These drugs mimic the building blocks of DNA or RNA and interfere with viral replication. Examples include acyclovir and tenofovir. • Protease Inhibitors: These drugs target viral proteases required for viral replication. They are commonly used in treating HIV and hepatitis C. • Polymerase Inhibitors: These drugs inhibit viral enzymes (e.g., reverse transcriptase, polymerase) involved in replicating the viral genome. Examples include zidovudine and sofosbuvir. • Neuraminidase Inhibitors: These drugs inhibit neuraminidase, an enzyme necessary for the release of new virus particles. Oseltamivir is a well-known example.
  • 4. Mechanism of Action • antiviral agents interfere with specific stages of the viral life cycle, including attachment, entry, replication, and release
  • 5. Mechanism of Action Attachment Inhibition: Viruses must first attach to specific receptors on the surface of host cells to initiate infection. Antiviral agents can interfere with this attachment process by: • Competitive Binding: These agents mimic host cell receptors and compete with the virus for binding sites. When the virus binds to the antiviral agent instead of the host cell receptor, it can't initiate infection. • Blocking Receptor Sites: Some drugs block or mask the viral binding sites on host cells, preventing the virus from attaching.
  • 6. Mechanism of Action Entry Inhibition:After attachment, the virus needs to enter the host cell. Antiviral agents can interfere with this step by: • Fusion Inhibition: Fusion inhibitors, like enfuvirtide for HIV, block the fusion of viral and cellular membranes, preventing the virus from entering the host cell. • Endocytosis Inhibition: Some antiviral drugs can inhibit the endocytosis process that viruses use to enter cells.
  • 7. Mechanism of Action Replication Inhibition: Once inside the host cell, viruses use the host's machinery to replicate their genetic material and produce new viral particles. Antiviral agents can disrupt this replication process by targeting: • Nucleoside/Nucleotide Analogues: These drugs resemble the building blocks of DNA or RNA and get incorporated into the viral genome during replication, causing mutations and preventing further replication. Examples include acyclovir and tenofovir. • Protease Inhibitors: These drugs target viral proteases required for processing viral proteins, preventing the formation of functional viral particles. They are commonly used in treating HIV and hepatitis C. • Polymerase Inhibitors: These drugs inhibit viral enzymes (e.g., reverse transcriptase, polymerase) involved in replicating the viral genome.
  • 8. Mechanism of Action Release Inhibition:After replication, viruses must exit the host cell to spread and infect other cells. Antiviral agents can interfere with this release step by: • Neuraminidase Inhibition: Neuraminidase is an enzyme required for the release of new virus particles from host cells. Inhibiting this enzyme prevents the release of viruses. Oseltamivir (Tamiflu) is an example used for influenza.
  • 9. Selectivity and Resistance • Selectivity of Antiviral Agents: • Antiviral agents are designed to specifically target viral processes, such as attachment, replication, or release, without interfering with normal host cell functions. This selectivity is essential for minimizing side effects and preserving the health of the host. • Selectivity is achieved by identifying unique viral targets or processes that are distinct from those found in host cells. For example, targeting viral enzymes or proteins that have no direct equivalent in human cells. • By specifically interfering with viral processes, antiviral agents aim to disrupt the viral life cycle while leaving host cell functions
  • 10. • Development of Drug Resistance: • Viruses can develop resistance to antiviral agents over time due to genetic mutations. This phenomenon is similar to the development of antibiotic resistance in bacteria. • When antiviral agents are used to treat viral infections, some viruses may acquire mutations in their genetic material that confer resistance to the drug. These mutations can occur naturally during viral replication. • Drug-resistant viral variants have changes in their viral targets (e.g., enzymes or proteins) that reduce the drug's ability to bind or inhibit the viral process effectively. As a result, the drug becomes less effective or completely ineffective against the resistant virus. • The emergence of drug-resistant viruses is a significant concern in
  • 11. Side effetcts • Gastrointestinal Disturbances: Many antiviral drugs can cause gastrointestinal side effects, including nausea, vomiting, diarrhea, or abdominal discomfort. Patients should be advised to take these medications with food or as directed to minimize these effects. • Fatigue: Fatigue is a common side effect of antiviral therapy. Patients may experience decreased energy levels and overall tiredness. • Headache: Headaches are often reported by individuals taking antiviral drugs, particularly during the initial stages of treatment. • Skin Reactions: Some antiviral drugs can lead to skin reactions, such as rashes, itching, or hypersensitivity reactions. Patients
  • 12. Side effetcts • Liver and Kidney Function: Certain antiviral drugs can affect liver or kidney function. Monitoring liver enzyme levels and kidney function through blood tests is essential to detect any abnormalities early. • Hematological Effects: Some antiviral drugs can cause hematological side effects, including anemia, neutropenia (low white blood cell count), or thrombocytopenia (low platelet count). Regular blood tests are necessary to monitor these parameters. • Psychiatric Symptoms: In some cases, antiviral therapy can lead to mood changes or psychiatric symptoms. Patients and caregivers should be educated about these potential side effects and encouraged to seek help if necessary
  • 14. Case Studies • Case Study 1:Patient Scenario: • A 28-year-old sexually active male presents with symptoms of painful genital sores and flu-like symptoms. He has a history of multiple sexual partners and has not been consistently using protection. A clinical evaluation and testing confirm a diagnosis of genital herpes (HSV-2 infection).
  • 15. Group Activity • Review the patient's medical history, symptoms, and diagnostic results. • Discuss the mechanisms of action of antiviral drugs used to treat HSV infections. • Recommend an appropriate antiviral treatment, including the drug name, dosage, and duration of therapy. • Consider the importance of patient education regarding transmission prevention and managing recurrent outbreaks.
  • 16. Case Studies • Case Study 2:Patient Scenario: • A 55-year-old patient with a history of intravenous drug use presents with persistent fatigue, abdominal pain, and dark urine. Laboratory tests show elevated liver enzymes, and further testing confirms a chronic hepatitis C infection.
  • 17. Group Activity • Explore the mechanisms of action of antiviral drugs used to treat chronic hepatitis C. • Consider the patient's medical history, current symptoms, and liver function tests. • Recommend an appropriate antiviral treatment regimen, including specific antiviral drugs, their doses, and duration. • Discuss the potential side effects and drug interactions and how to monitor and manage them. • Highlight the importance of adherence and regular monitoring to assess treatment response.
  • 18. CASE STUDIES • Case Study 3:Patient Scenario: • A 45-year-old healthcare worker tests positive for COVID-19. The patient is mildly symptomatic with fever, cough, and fatigue. They have no known allergies or significant comorbidities.
  • 19. Group Activity • Research and discuss the available antiviral treatments for COVID-19. • Consider the patient's mild symptoms, occupation, and comorbidities. • Recommend an appropriate antiviral treatment strategy, including specific drugs (if applicable), dosages, and duration. • Discuss potential side effects and monitoring parameters for COVID-19 treatment. • Emphasize the importance of isolation, infection control